title: Heregulin and agonistic anti-p185(c-erbB2) antibodies inhibit proliferation but increase invasiveness of breast cancer cells that overexpress p185(c-erbB2): increased invasiveness may contribute to poor prognosis.
abstract: Overexpression of p185(c-erbB2) (p185/NEU/HER2) by tumor cells is associated with a poor prognosis in many but not all studies of breast and ovarian cancer. The poor prognosis associated with overexpression of p185(c-erbB2) could result from an increased growth rate or increased invasive potential. The p185(c-erbB2) tyrosine kinase receptor can be activated with agonistic antibodies directed against p185(c-erbB2) or with the ligand heregulin through a combinatorial interaction with erbB3 or erbB4. Consequently, we have asked whether heregulin or agonistic antibodies increase anchorage-independent growth or invasiveness of the SKBr3 breast cancer cell line, which overexpresses p185(c-erbB2). Incubation of SKBr3 breast cancer cells with heregulin inhibited anchorage-independent growth while enhancing tyrosine phosphorylation of p185(c-erbB2). Heregulin treatment also increased adhesion of SKBr3 cells to plastic and increased invasiveness of tumor cells into Matrigel membranes while increasing expression of the CD44 (HCAM) and CD54 (ICAM-1) adhesion molecules. Tumor cell invasion of Matrigel membranes was partially blocked by either anti-CD44 or anti-CD54 antibodies, indicating a role for these adhesion molecules in the invasion process. Compatible with the increased invasiveness, heregulin increased expression of the matrix metalloproteinase 9. In contrast, the agonistic anti-p185(c-erbB2) antibody ID5 induced only a subset of the responses induced by heregulin. ID5 induced tyrosine phosphorylation of p185(c-erbB2), increased invasiveness, and increased expression of CD44. Despite the similarity of effects of ID5 and heregulin on some outcomes, the ID5 antibody failed to increase adhesion to plastic, expression of CD54, or production of matrix metalloproteinase 9. Thus, the ID5 agonistic anti-p185(c-erbB2) antibody mimics rather than antagonizes some but not all of the actions of heregulin. Moreover, the poor prognosis of breast and ovarian cancers that overexpress p185(c-erbB2) could relate in part to enhanced invasiveness rather than to increased proliferative capacity.
authors.affiliation: Division of Medicine, University of Texas, M.D. Anderson Cancer Center, Houston, Texas 77030, USA.
authors.forename: F J
authors.initials: FJ
authors.lastname: Xu
authors.forename: S
authors.initials: S
authors.lastname: Stack
authors.forename: C
authors.initials: C
authors.lastname: Boyer
authors.forename: K
authors.initials: K
authors.lastname: O'Briant
authors.forename: R
authors.initials: R
authors.lastname: Whitaker
authors.forename: G B
authors.initials: GB
authors.lastname: Mills
authors.forename: Y H
authors.initials: YH
authors.lastname: Yu
authors.forename: R C
authors.initials: RC
authors.lastname: Bast
mesh_terms: D000912:Antibodies, Neoplasm / Q000494:pharmacology* / Q000633:toxicity; D000918:Antibody Specificity; D001943:Breast Neoplasms / Q000235:genetics / Q000378:metabolism / Q000473:pathology*; D002448:Cell Adhesion / Q000187:drug effects; D002455:Cell Division / Q000187:drug effects; D003094:Collagen; D017364:Collagenases / Q000096:biosynthesis / Q000235:genetics; D004338:Drug Combinations; D005260:Female; D018734:Genes, erbB-2; D006023:Glycoproteins / Q000037:antagonists & inhibitors / Q000276:immunology*; D006131:Growth Inhibitors / Q000494:pharmacology* / Q000633:toxicity; D006801:Humans; D018960:Hyaluronan Receptors / Q000096:biosynthesis / Q000235:genetics; D018799:Intercellular Adhesion Molecule-1 / Q000096:biosynthesis / Q000235:genetics; D007797:Laminin; D020780:Matrix Metalloproteinase 9; D009361:Neoplasm Invasiveness; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors / Q000096:biosynthesis / Q000235:genetics / Q000276:immunology*; D020880:Neuregulins; D010766:Phosphorylation / Q000187:drug effects; D010969:Plastics; D011499:Protein Processing, Post-Translational / Q000187:drug effects; D011509:Proteoglycans; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000037:antagonists & inhibitors / Q000276:immunology* / Q000378:metabolism; D014407:Tumor Cells, Cultured / Q000187:drug effects
chemical_list: D000912:Antibodies, Neoplasm; D003094:Collagen; D017364:Collagenases; D004338:Drug Combinations; D006023:Glycoproteins; D006131:Growth Inhibitors; D018960:Hyaluronan Receptors; D018799:Intercellular Adhesion Molecule-1; D007797:Laminin; D020780:Matrix Metalloproteinase 9; D009363:Neoplasm Proteins; D020880:Neuregulins; D010969:Plastics; D011509:Proteoglycans; D018719:Erb-b2 Receptor Tyrosine Kinases; C059485:matrigel